• Gefitinib - Wikipedia, the free encyclopedia

    en.wikipedia.org/wiki/Gefitinib Gefitinib (ZD1839) (INN, / ɡ ɛ ˈ f ɪ t ᵻ n ɪ b /, trade name Iressa, marketed by AstraZeneca and Teva), is a drug used for certain breast, lung and other cancers.
  • Gefitinib - National Cancer Institute

    www.cancer.gov/about-cancer/treatment/drugs/gefitinib This page contains brief information about gefitinib and a collection of links to more information about the use of this drug, research results, and ongoing clinical ...
  • Gefitinib

    gefitinib.org Gefitinib. Gefitinib is a cancer treatment marketed under the brand name Iressa. It is not a chemotherapeutic in the traditional sense, since it does not cause the ...
    • IRESSA® (gefitinib) | Information and resources

      www.iressa-usa.com Learn about IRESSA® (gefitinib), now approved for first-line treatment of EGFR mutation–positive patients with metastatic NSCLC
    • Gefitinib: MedlinePlus Drug Information

      www.nlm.nih.gov/medlineplus/druginfo/meds/a607002.html Gefitinib comes as a tablet to take by mouth. It is usually taken with or without food once a day. Take gefitinib at around the same time every day.
    • Gefitinib (Iressa®) - Cancer Information - Macmillan Cancer ...

      www.macmillan.org.uk/Cancerinformation/Cancertreatment/.../Gefitinib.aspx Information about a drug called Gefitinib (Iressa®), which may be used to treat non-small cell lung cancer (NSCLC) or other types of cancer as part of a research trial
    • Gefitinib - National Institutes of Health

      livertox.nih.gov/Gefitinib.htm Introduction . Gefitinib is a selective tyrosine kinase receptor inhibitor used in the therapy of non-small cell lung cancer. Gefitinib therapy is ...